Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Mechanisms of action of GLP-1RAs

10' education - Oct. 21, 2019 - Prof. Filip Knop, MD

GLP-1RA: where do they fit in CV risk management?

10' education - Oct. 21, 2019 - Prof. John Deanfield, MD

Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM

5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD

Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD

A transatlantic discussion on the new LDL-c guidelines: What are the key differences?

10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD

A revolution in treatment of HFrEF with a SGLT2 inhibitor

5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD

The diabetes challenge for cardiologists: The key things to understand

10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition

10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD

The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM

10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD

Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?

10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME

Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?

10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD

Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD

3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg

DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI

3' education - Sep. 1, 2019 - Prof. Deepak Bhatt

Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes

3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray

The science behind vascular and renal benefits of GLP-1 receptor agonists

10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD

Importance of protection and prevention in diabetic cardiorenal disease

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD

Heart failure and diabetes: What is the goal of treatment?

10' education - July 17, 2019 - Prof. John McMurray, MD

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

Phase III trial with SGLT2i in CKD patients stopped early due to overwhelming efficacy

News - Mar. 31, 2020

The phase III DAPA-CKD trial evaluating the effectivity of SGLT2 inhibitor dapagliflozin in patients with CKD will be stopped early due to overwhelming benefit.

Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020
COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.

ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.

NOAC plus aspirin reduces CV events in stable CAD and/or PAD patients with and without diabetes

News - Mar. 29, 2020
This pre-specified analysis of the COMPASS trial showed that low-dose rivaroxaban plus aspirin reduces CV events compared to aspirin alone in patients with CAD and/or PAD, irrespective of the presence of diabetes.

ACC 2020 This pre-specified analysis of the COMPASS trial showed that low-dose rivaroxaban plus aspirin reduces CV events compared to aspirin alone in patients with CAD and/or PAD, irrespective of the presence of diabetes.

Irregular sleep duration and timing associated with increased risk of CVD

Literature - Mar. 24, 2020 - Huang T et al., - J Am Coll Cardiol. 2020.

Using data from the MESA study, it was demonstrated that individuals with irregular sleep duration and timing have increased risk of CVD.

New FDA draft guidance for industry to evaluate safety of new T2DM drugs

News - Mar. 11, 2020

The FDA has released a draft guidance for industry on the evaluation of safety of new T2DM drugs, and has withdrawn the guidance from 2008 with recommendations for evaluation of CV risk.

Need for improvement of screening and management of CAD patients with dysglycemia

Literature - Mar. 5, 2020 - Ferrannini G et al., - Diabetes Care 2020

An analysis of the EUROASPIRE V survey showed that dysglycemia in CAD patients was unrecognized in a large portion of patients, while two thirds of CAD patients have T2DM or IGT.

PCSK9 inhibitor reduces atherogenic lipids in T2DM patients with mixed dyslipidemia

Literature - Feb. 27, 2020 - Colhoun HM, et al. - Cardiovasc Diabetol 2020

This post hoc analysis of the DM-DYSLIPIDEMIA study shows that, in a high risk subgroup of T2DM patients with mixed dyslipidemia, alirocumab treatment is more effective in reducing ApoB and non-HDL-c as compared to usual treatment.

SGLT2i reduces atrial fibrillation and atrial flutter in T2DM

Literature - Feb. 17, 2020 - Zelniker TA et al. - Circulation 2020

The SGLT2 inhibitor dapagliflozin reduced time to first event of atrial fibrillation and atrial flutter as well as total events in T2DM patients, shown in a post-hoc analysis of the DECLARE-TIMI 58 trial.

Baseline HbA1c levels associated with CV outcomes in high risk T2DM patients

Literature - Feb. 10, 2020 - Menon V et al., - J Am Heart Assoc. 2020.

This subanalysis of the ACCELERATE trial showed that HbA1c levels at study baseline are associated with CV outcomes in T2DM patients with a history of coronary artery disease and on optimal medical therapy.

Screening for diabetes in black barbershops

Literature - Feb. 5, 2020 - Osorio M et al., - JAMA Intern Med. 2020.

This study evaluated a community-based screening approach in 8 barbershops in Brooklyn, New York and found a prevalence of undiagnosed diabetes in 9.0% of the black male participants.

2019 CVD statistics in ESC member countries

News - Feb. 3, 2020

The European Society of Cardiology (ESC) Atlas working group has published a report on CVD statistics in 2019 across 56 member countries of the ESC.

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD
Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment (liraglutide and semaglutide) in T2DM patients with peripheral artery disease.

Prof. Verma shares the data of subanalyses of the LEADER and SUSTAIN-6 trials on the effect of GLP-1RA treatment in T2DM patients with peripheral artery disease.